SB Hycamtin Approved As Second-Line Therapy For SCLC
Executive Summary
SmithKline Beecham's Hycamtin was approved Nov. 30 for "the treatment of small cell lung cancer sensitive disease after failure of first-line chemotherapy." Hycamtin (topotecan) is the first single agent approved for second-line use in the disease.